

QMS MEDICAL ALLIED SERVICES LIMITED CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURE OF UNPUBLISHED PRICESENSITIVE INFORMATION

Qms Medical Allied Services Limited ("**The Company**") is committed to fair disclosure of information about the Company without advantage to any particular person(s). The Company will adhere to the following principles for fair disclosure of Unpublished Price Sensitive Information relating to the Company and/ or its securities without diluting the provisions specified in SEBI (Prohibition of Insider Trading Regulations), 2015, ("**Insider Trading Regulations**").

- 1. The Company shall promptly make disclosure about any Unpublished Price Sensitive Information that would impact discovery no sooner than credible and concrete information comes into being and as soon as the information or the decisions are validated by the Board of Directors of the Company to NSE Limited ("NSE") and upload such information on the Company's official website in order to make such information generally available to investors and members of the Company.
- 2. The Company shall make uniform and universal dissemination of Unpublished Price Sensitive Information to avoid selective disclosure by disclosing the information to NSE, immediately, and simultaneously uploading the same on the Company's website.
- 3. In case of selective disclosure of Unpublished Price Sensitive Information inadvertently or otherwise, the Company shall make prompt dissemination of such Unpublished Price Sensitive Information to ensure that such information is generally available.
- 4. The Company Secretary & Compliance Officer of the Company shall act as the Chief Investor Relations Officer of the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015 to deal with dissemination of information and disclosure of Unpublished Price Sensitive Information.
- 5. Unpublished Price Sensitive Information shall be handled on a "need-to-know" basis i.e. Unpublished Price Sensitive Information shall be disclosed only to those within the Company, who need the information to discharge their duty.



Oms Medical Allied Services Limited

CODE OF CONDUCT TO REGULATE, MONITOR AND REPORT TRADING BY INSIDERS

1. PREAMBLE

- 1.1. Qms Medical Allied Services Limited, the Company endeavours to preserve the confidentiality of Unpublished Price Sensitive Information and to prevent the misuse of such information. The Company is committed to transparency, fairness in dealing with all the stakeholders and in ensuring adherence to all laws and regulations in force.
- 1.2. The Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015,(the "Regulations"), which replace the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992, as amended, make it mandatory for every public listed company to lay down a code of conduct for regulation, monitoring and reporting of insider trading by employees of the Company, including directors, and other "connected persons" (as defined in the Regulations), in relation to the securities of the Company (this "Code" or the "Code").
- 1.3. This Code is applicable to every Designated Employee of the Company (as defined below), their Immediate Relatives (as defined below) and other connected persons (as defined in the Regulations) (together referred to as "Designated Persons"), and each such Designated Person has a duty to safeguard the confidentiality of all information obtained, including during the course of his or her employment at the Company.

2. <u>DEFINITIONS AND INTERPRETATIONS</u>

Definitions

2.1. Terms used but not defined herein, shall unless the context requires otherwise have the meaning assigned to them below:

"Act" or "SEBI Act" means the Securities and Exchange Board of India Act, 1992.

"Board" or "Board of Directors" means the Board of Directors of the Company or any Committee thereof;

"Code" or "Code of Conduct" shall mean the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of trading by insiders of Qms Medical Allied Services Limited as amended from time to time.

Company means Qms Medical Allied Services Limited

Compliance Officer means Company Secretary or such other senior officer, who is



financially literate and is capable of appreciating requirements for legal and regulatory compliance under the Regulations designated so and reporting to the Board of Directors and who shall be responsible for compliance of policies, procedures, maintenance of records, monitoring adherence to the rules for the preservation of Unpublished Price Sensitive Information, monitoring of trades and the implementation of the codes specified in the Regulations under the overall

supervision of the Board of Directors of the Company and other requirements under the Regulations;

Connected Person means:

- (i) Any person who is or has during the six months prior to the concerned act been associated with a Company, directly or indirectly, in any capacity including by reason of frequent communication with its officers or by being in any contractual, fiduciary or employment relationship or by being a director, officer or an employee of the Company or holds any position including a professional or business relationship between himself and the Company whether temporary or permanent, that allows such person, directly or in directly, access to Unpublished Price Sensitive Information or is reasonably expected to allow such access.
- (ii) Without prejudice to the generality of the foregoing, the persons falling within the following categories shall be deemed to be connected persons unless the contrary is established, -
 - (a) an immediate relative of connected persons specified in clause (i); or
 - (b) a holding company or associate company or subsidiary company; or
 - (c) an intermediary as specified in Section 12 of the Act or an employee or direct or thereof; or
 - (d) an investment company, trustee company, asset management company or an employee ordirector thereof; or
 - (e) an official of a stock exchange or of clearing house or corporation; or
 - (f) a member of board of trustees of a mutual fund or a member of the board of directors of the asset management company of a mutual fund or is an employee thereof; or
 - (g) a member of the board of directors or an employee, of a public financial institution as defined in section 2(72) of the Companies Act, 2013; or
 - (h) an official or an employee of a self-regulatory organization recognised or authorised by the Board; or
 - (i) a banker of the Company; or



(j) a concern, firm, trust, hindu undivided family, company or association of persons wherein a director of the Company or his immediate relative or banker of the Company, has more than ten per cent, of the holding or interest.

Dealing in Securities means subscribing, buying, selling or agreeing to subscribe, buy, sell or deal in any securities either as principal or agent;

Designated Employee means: (a) All directors of the Company; (b) All employees of the rank of General Manager and above of the Company; (c) All employees of the rank of Manager and above in the finance and accounts, legal and secretarial and internal audit function/department; and (d) any other employee of the Company designated by the Board of Directors in consultation with the Compliance Officer, from time to time;

Director means a member of the Board of Directors;

Employee means every employee of the Company including the Directors in the employment of the Company;

Financial results mean the half yearly or annual financial statements of the Company;

Generally Available Information means information that is accessible to the public Compliance Officer a non-discriminatory basis;

Immediate Relative for the purpose of this Code means spouse of a Designated Employee, and includes parent, sibling and child of such Designated Employee or of the spouse, any of whom is either dependent financially on such Designated Employee or consults such Designated Employee in taking decisions relating to trade in Securities;

Insider means any person who is (a) a "Connected Person" or (b) any person in possession of or having access to Unpublished Price Sensitive Information;

Key Managerial Person means person as defined in Section 2(51) of the Companies Act, 2013;

Listing Agreement means the listing agreements entered into/to be entered into by the Company with the stock exchanges, as amended;

Prohibited Period means the period of time when the trading Window is closed and as specified in clause 5;



Promoter shall have the meaning assigned to it under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 or any modification thereof.

SEBI means the Securities and Exchange Board of India;

Securities shall have the meaning assigned to it under the Securities Contracts (Regulation) Act, 1956 (42 of 1956) or any modification thereof except units of a mutual fund;

Takeover regulations mean the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and any amendments thereto;

Trading means Dealing in Securities of the Company;

Specified Persons means the Directors, Connected persons, the Insiders, the Designated Employees, Promoters and their immediate relatives collectively

Trading Window means the period of time when trading is allowed; and

Unpublished Price Sensitive Information means any information, relating to a company or its securities, directly or indirectly, that is not generally available which upon becoming generally available, is likely to materially affect the price of the securities and shall, ordinarily including but not restricted to, information relating to the following: –

Words and expressions used and not defined in this Code but defined in the Regulations, Act, Companies Act,2013, the Securities Contracts (Regulation) Act, 1956 (42 of 1956) or the Depositories Act, 1996 (22 of 1996) shall have the meanings respectively assigned to them in those legislations, as amended from time to time.

Interpretations

- 2.2. This Code shall be interpreted as follows:
 - 2.2.1. terms that have not been defined in the Code shall have the meaning assigned to them in the Regulations;
 - 2.2.2. this Code can be modified/amended/altered only by the Board of Directors subject to the condition that such alteration shall not be inconsistent with the provisions of the Regulations;
 - 2.2.3. reference to a statute or a statutory provisions includes to the extent applicable at any prevalent time: (a) that statute or statutory provision as from time to time consolidated, modified, re-enacted, replaced by any statute



or statutory provision; and (b) any subordinate legislation or regulation made under the relevant statute or statutory provision;

- 2.2.4. Unless the context otherwise requires, all words (whether gender specific or gender neutral) shall be deemed to include each of the masculine, feminine and neuter genders and words importing the singular include the plural and vice-versa; and
- 2.2.5. Any reference to a person includes any individual, firm, corporation, partnership, company, trust, association, joint-venture, government or agency or political subdivision thereof or other entity of any kind, whether or not having separate legal personality. A reference to any person in this Code shall when the context permits include such person's executives, administrators, heirs, legal representatives and permitted successors and assigns.

3. **COMPLIANCE OFFICER**

- 3.1. The Company has designated the Company Secretary as the Compliance Officer. The Compliance Officer shall report to the Board of the Company and in particular, shall provide reports annually to the Chairman of the Board or the Chairman of the Audit Committee.
- 3.2. The Compliance Officer shall be responsible for, inter alia, the following;
 - 3.2.1. maintenance of records required under the Regulation including (i) the record of Designated Employees and any changes made in the list of Designated Employees; and (ii) a record of declarations for a minimum period of five years;
 - 3.2.2. in consultation with the Chairman of the Company and as directed by the Board, the specification and announcement of a prohibited period;
 - 3.2.3. maintenance of record of Prohibited Periods specified from time to time; and
 - 3.2.4. Setting forth policies, procedures, monitoring adherence to the rules for the preservation of Unpublished Price Sensitive Information, approval of the trading, plan pre-clearing of Designated Persons, monitoring of trading and the implementation of this Code under the overall supervision of the Board.



4. UNPUBLISHED PRICE SENSITIVE INFORMATION

Preservation of Unpublished Price Sensitive Information

4.1. Designate Persons shall maintain the confidentiality of all Unpublished Price Sensitive Information and shall not pass on such information to any person directly or indirectly by way of making a recommendation for the purchase or sale of Securities.

Need to Know

4.2. All information is to be handled within the Company on a "need-to-know" basis and no Unpublished Price Sensitive Information should be communicated to any person except in furtherance of the Insider's legitimate purposes, performance of duties or discharge of his legal obligations.

Limited access to confidential information

- 4.3. Files containing confidential information shall be kept secured. Computer files must have adequate security of login and password, etc. Files containing confidential information should be deleted/destroyed after its use. No such related documents should be kept lying at any place accessible to other employees/persons.
- 4.4. If any Designated Person wants to cross the "Chinese Wall", they shall seek permission from the Compliance Officer in writing stating the reasons/justification for doing so, which permission shall be obtained from the Board. The Compliance Officer shall require such Designated Person to produce an undertaking that the information will not be shared with any other person except as permitted and neither he nor the person with whom the information is shared or their Immediate Relatives shall trade in or induce others to trade in the Securities of the Company.

5. PROHIBITION OF INSIDER TRADING

Prohibition

- 5.1. No insider shall:
 - 5.1.1. Trade in Securities of the Company, either on their own behalf or on behalf of any other person when in possession of any Unpublished Price Sensitive Information; or
 - 5.1.2. Communicate, provide or allow access to any Unpublished Price Sensitive Information or Securities listed or proposed to be listed to any person including other insiders except where such communication is for legitimate purposes, performance of duties or discharge of legal obligations.



Trading plan

5.2. An Insider shall be entitled to formulate a trading plan and present it to the Compliance Officer for approval and public disclosure pursuant to which trades may be carried out on his behalf in accordance with such plan and subject to the Regulations.

Trading Restrictions

- 5.3. Designated Persons shall not indulge in Trading during a Prohibited Period.
- 5.4. The following events shall trigger a prohibited period, the duration of which shall be in accordance with clause 5.5 below:
 - 5.4.1. declaration of financial results;
 - 5.4.2. declaration of dividends, whether interim or final;
 - 5.4.3. issue of securities by way of public issue, rights issue or bonus issue;
 - 5.4.4. acquisition, amalgamation, merger, de-merger, take-over of companies/businesses, delisting, disposals or expansion of business, new projects or such other transactions in respect of the Company;
 - 5.4.5. buy-back and splitting of Securities or any other change in capital structure;
 - 5.4.6. changes in key managerial personnel;
 - 5.4.7. any change in policies, plans or operations of the Company;
 - 5.4.8. material events in accordance with the Listing Agreement.
- 5.5. The Prohibited Period shall begin on earlier of (i) seven days before the day on which the meeting of the Board of Directors is proposed to be held to consider the events set out in Clause 5.4; and (ii) the date of circulation of agenda papers pertaining to any of the events set out in Clause 5.4 above. The Trading Window shall open 48 hours after the close of the board meeting at which decisions in respect of the above events is made public, whichever is later, or at a later date as may be determined by the Compliance Officer. The Company shall intimate the beginning of the Prohibited Period to all Designated Persons in theform annexed hereto as Annexure I.
- 5.6. Designated Persons shall undertake trading only when the trading window is open and shall not trade during the Prohibited Periods or all other periods when the Compliance Officer determines that a Designated Person or class of Designated



Persons can reasonably be expected to have possession of Unpublished Price Sensitive Information.

- 5.7. The Compliance Officer shall confidentially maintain a list of Securities as a "restricted list" which shall be used as a basis for approving or rejecting applications for preclearance of trades.
- 5.8. The Trading Window and Prohibited Period shall also be applicable to any person having contractual or fiduciary relation with the Company, such as auditors, accountancy firms, law firms, analysts, consultants, etc., assisting or advising the Company.
- 5.9. Options under an ESOP may be exercised during a Prohibited Period. However sale of Securities allotted on exercise of such options shall not be allowed during a Prohibited Period.

Pre-clearance or pre-dealing of Trading

- 5.10. When the trading window is open, any Designated Person shall trade in Securities of the Company subject to pre-clearance by the Compliance Officer if the value of the proposed trades is equal to or above Rs.10 Lacs. However, no Designated Person shall be entitled for pre-clearance of any proposed trade if such Designated Person is in possession of UPSI if the trading window is not closed.
- 5.11. An application for pre-clearance of Trading shall be made out to the Compliance Officer substantially in the form set out in Annexure II.
- 5.12. The application shall incorporate, *inter alia*, the following clauses:
 - 5.12.1.the estimated number of securities that the Designated Person intends to deal in, the details as to the depository with which he has a security account, the details as to the Securities in such depository mode and such other details as may be required by the Compliance Officer;
 - 5.12.2.An undertaking (as per Annexure III) shall be executed in favour of the Compliance Officer and the Company, by such Designated Person which shall inter alia state that the applicant is not in possession of any Unpublished Price Sensitive Information.
- 5.13. If the application for pre-clearance has been duly completed in accordance with Annexure II and Annexure III, the Compliance Officer shall grant approval, at his sole discretion, within (2) working days from the date of acknowledgement substantially in the form set out in Annexure IV.
- 5.14. the Compliance Officer shall retain copies of all applications and acknowledgements.



Other Restrictions

- 5.15. Within one week of the grant of pre-clearance approval under clause 5.13, the relevant Designated Person shall complete the proposed transaction in respect of which such approval was granted. If such transaction is not completed within the period of one week, the relevant Designated Person must seek a fresh pre- clearance in accordance with the Code.
- 5.16. The Designated Person shall make declarations of pre-clearance transactions substantially in the form set out in Annexure V. Even in cases where the transaction has not been undertaken, the same should be reported by the Designated Person in the above format together with reasons for non-execution of the trade. The Compliance Officer shall maintain a record of the reasons provided in relation to the non-execution of trades by Designated Persons who have secured pre-clearance.
- 5.17. Designated Persons who trade in any Securities of the Company shall not execute a contra trade during the next six months following the prior transaction. To the extent permitted under the Regulations, the Compliance Officer may, in his discretion, grant relaxations from this restriction for reasons to be recorded in writing provided that such relaxation does not violate the Regulations. In case a contra trade is executed inadvertently or otherwise in violation of such restriction the profit from such trade shall be liable to be disgorged for remittance to the Securities and Exchange Board of India for credit to the investor protection and education fund administered by it under the SEBI Act. In case of subscription for Securities in the primary market (IPO) and to the extent required under the Regulations, Designated Persons shall hold their investments for a minimum period of 30 days commencing from the allotment of the relevant Securities to such Designated Persons.
- 5.18. For the avoidance of doubt, equity shares allotted or granted to designated employees pursuant to an ESOP shall not be subject to the restrictions on holding securities prescribed herein.

6. **DISCLOSURES**

6.1 Initial Disclosure

Every promoter, key managerial personnel and director of the company and any other person for whom such persons takes trading decisions shall disclose his holding of securities of the company as on the date of these regulations taking effect within thirty days in Form A;

Every person on appointment as a key managerial personnel or a director of the company or Designated Employee or upon becoming a promoter shall disclose his holding of securities of the company and any other person for whom such persons



takes trading decisions as on the date of appointment or becoming a promoter, to the company within seven days of such appointment or becoming a promoter in Form B.

6.2 Continual Disclosure

Every promoter, designated employee and director of company and any other person for whom such persons takes trading decisions shall disclose to the company the number of such securities acquired or disposed of within two trading days of such transaction if the value of the securities traded, whether in one transaction or a series of transactions over any calendar quarter, aggregates to a traded value in excess of ten lakh rupees or such other value as may be specified by the Compliance Officer from time to time in Form C;

6.3 Disclosure by the Company to the Stock Exchange(s):

The company shall notify the particulars of such trading as mentioned in clause 6.2 to the stock exchange on which the securities are listed within two trading days of receipt of the disclosure or from becoming aware of such information.

7. RECORDS OF DISCLOSURES RECEIVED BY THE COMPANY

- 7.1. The Compliance Officer shall maintain records of all declarations in the appropriate form made by the Designated Persons for a minimum period of five years. The Compliance Officer shall also maintain a record of the Designated Employees and any changes made in the list of the Designated Employees.
- 7.2. The Compliance Officer shall place before the Managing Director of the Company on a monthly basis, all the details of the dealing in the Securities by the Designated Persons of the Company together with the accompanying documents provided by the Designated Persons in accordance with this Code.

8. PENALTIES FOR CONTRAVENTION

- 8.1. Specified persons who violate the Code shall be subject to appropriate Disciplinary Action.
- 8.2. The Disciplinary Action taken by the Company shall not preclude SEBI from taking any action if a violation of this Code also results in a violation of the Regulations.



9. <u>INFORMATION</u>

Where there is a violation of the Regulations, the Compliance Officer or the Company shall immediately inform SEBI about such violation.

10. **GENERAL**

All Specified Persons are advised to review this Code and the Regulations carefully and acquaintthemselves with all the provisions contained therein.



ANNEXURE I

DRAFT OF E-MAIL FOR INTIMATING CLOSURE OF TRADING WINDOW

Subject: Urgent: Insider Trading- Restrictive period

To: All Directors, Employees of the Company,
The Board meeting for approvingshall be held on
This is a reminder to you for taking prior approval before sharing sensitive information to any person to comply with SEBI (Insider Trading) Regulations, 2015.
You are hereby informed that you shall not share any sensitive information of the company without taking written prior approval of the Compliance Officer.
Further if in case you receive the sensitive information of the company you shall immediately intimate us for the compliance purpose.
You are requested to comply with the above immediate effect and on-going basis.
Thank you for your co-operation in this regard,



ANNEXURE II

SPECIMEN OF APPLICATION FOR PRE-CLEARANCE OF TRADE IN SECURITIES

Date:

To, The Compliance Officer, Qms Medical Allied Services Limited

Dear Sir/Madam,

Application for pre-clearance of trade in securities of the Company

Pursuant to the SEBI (Prohibition of Insider Trading) Regulations,2015 and the Code, I seek approval to purchase/Sale/ subscription of__Securities of the Company as per details given below:

1	Name of the Applicant	
2	Designation	
3	Number of securities held as on date(including through immediate relatives)	
4	Folio No. / DP ID/ Client ID No.	
5	The proposal is for	A) Purchase of Securities B) Subscription to securities C) Sale of Securities
6	Proposed date of dealing in securities	
7	Estimated number of securities proposed to be dealt	
8	Price at which the transaction is proposed	
9	Current market price (as on date of application)	
10	Name of the immediate relative and relation if the transaction is in the name of the immediate relative	
11	Whether the proposed transaction will be through stock exchange or off-market deal	
12	Folio no./DP ID/ Client Id No. where the securities will be credited/debited.	

🗣 1A-1B / 2A-2B, Navkala Bharati Building, Plot No. 16, Prabhat Colony, Road No. 3, Santacruz (East), Mumbai - 400 055.

☎ +91-022 - 6288 1111 **@** www.qmsmas.com



I enclose here with the form of Undertaking signed by me.

Yours faithfully

(Signature of

Employee) Name:

Designation:



ANNEXURE III

FORMAT OF UNDERTAKING TO BE ACCOMPANIED WITH THE APPLICATION FOR **PRE-CLEARANCE**

UNDERTAKING

Date:
To, The Compliance Officer, Qms Medical Allied Services Limited
I,of the Company, residing atam desirous of dealing in *Securities of the Company as mentioned in my application datefor pre-clearance of the transaction.
I hereby declare that I am not in possession of or otherwise privy to any Unpublished Price Sensitive Information (asdefined in this Code up to the time of signing this Undertaking.
I further declare that I cannot be deemed to be in possession of or otherwise privy to any Unpublished Price Sensitive Information for the reason that
In the event that I have access to or receive any information that could be construed as "Unpublished Price Sensitive Information" as defined in the Code, after the signing of this undertaking but before executing the transaction for which approval is sought, I shall inform the Compliance Officer of the same and shall completely refrain from dealing in the Securities of the Company until such information becomes public.
I declare that I shall hold the Securities for a minimum period of 6 months from the date of purchase and shall not enter into opposite transaction within 6 months/I have complied with the requirement of the minimum holding period of 6 months with respect to shares sold.
I declare that I have not contravened the provisions of the Code as notified by the Company from time to time.
I undertake to submit the necessary report within two days of execution of the transaction/a 'Nil' report if the transaction is not undertaken.
Medical Allied Services Ltd.



If approval is granted, I shall execute the deal within 7 trading days of the receipt of approval failing which I shall seek fresh pre-clearance and shall not execute my order until such pre-clearance is obtained.

I declare that I have made full and true disclosure in the matter. Signature:
Name:
Designation:
* To disable group have of all access



ANNEXURE IV

FORMAT FOR PRE-CLEARANCE ORDER
To, Name Designation Place:
This is to inform you that your request for dealing in (numbers) Securities of the Company as mentioned in your application dated_is approved. Please note that the said transaction must be completed on orbefore(date) that is within 7 trading days from today.
In case you do not execute the approved transaction /deal on or before the aforesaid date you would have to seek fresh pre-clearance before executing any transaction/deal in the securities of the Company. Further, you are required to file the details of the executed transactions in the attached format within 2 trading days from the date of transaction/deal. In case the transaction is not undertaken a 'Nil' report shall be necessary together with reasons for non-execution of the trade.
Yours faithfully, For QMS MEDICAL ALLIED SERVICES LIMITED
COMPLIANCE OFFICER Date:
Encl: Format for submission of details of transaction



ANNEXURE V

FORMAT FOR DISCLOSURE OF TRANSACTIONS

(To be submitted within 2 trading days of transaction /dealing in securities of the Company)

To,
The Compliance Officer, **Qms Medical Allied Services Limited**

I hereby inform that I (including through my Immediate Relative)

- have not bought / sold/ subscribed any securities of the Company for the following reasons_
- have bought/sold/ subscribed to_securities as mentioned below on__(date)

	DP ID/Client ID /Folio No	Price (Rs.)

In connection with the aforesaid transaction(s), I hereby undertake to preserve, for a period of 3 years and produce to the Compliance officer / SEBI any of the following documents:

- i. Broker's contract note.
- ii. Proof of payment to/from brokers
- iii. Extract of bank passbook/statement(to be submitted in case of demat transaction)
- iv. Copy of Delivery instruction slip(applicable in case of sale transaction)

I agree to hold the above securities for a minimum period of six months. In case there is any urgent need to sell these securities within the said period, I shall approach the Compliance Officer for necessary approval along with reasons in writing. (Applicable in case of purchase / subscription).



I declare	that the	above	info	rmation	is	cor	rect	and	that	no	provisions	of	the	Code	and	/or
applicable	laws/re	egulatio	ons	have	be	en	cont	trave	ened	for	effectin	g	the	above	e s	aid
transactio	ns(s).															

Date:	
Signature:	
Name:	
Designation:	



FORM A

Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015[Regulation 7 (1) (a) read with Regulation 6 (2)]

Name of the company: QMS MEDICAL ALLIED SERVICES LIMITED

Details of Securities held by Promoter, Key Managerial Personnel (KMP), Director and other such persons as mentioned in Regulation 6(2)

Name, PAN No., CIN/DIN & address with	Category of Person (Promote rs/KMP / Directors/im me diate relatives/ot	Securities held as on the date of regulation coming into force		% of Shareholdi ng	Open Int of the Fut contracts as on the of regula coming i force	ture s held date tion	Open Int of the Op Contract: as on the of regula coming i force	tion s held date tion
contact nos.	hersetc)	Type of securi ty(For eg Shares, Warrants , Convertib le Debentur es etc.)	No.		Numb er of units (contra cts * lot size)	Notion al value in Rupee terms	Numb erof units (contra cts * lot size)	Notion al value in Rupe e term s
1	2	3	4	5	6		/	

Note: "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of InsiderTrading) Regulations, 2015.

Signature:		
Designation:		
Date:		
Place:		



FORM B

Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015[Regulation 7 (1) (a) read with Regulation 6 (2)]

Name of the company: QMS MEDICAL ALLIED SERVICES LIMITED

Details of Securities held on appointment of Key Managerial Personnel (KMP) or Director or upon becoming a Promoter of a listed company and other such persons as mentioned in Regulation 6(2).

Name , PAN No., CIN/D IN & addre ss with conta ct nos.	Category of Person (Promote rs/KMP / Directors/ imme diate relatives/o thers etc)	Date of appoint ment of Director /KMP OR Date of becoming Promot er	Securities held at the time of becoming Promoter/appoi ntment of Director/KMP		% of Shareho Iding	the Future contract held at the ti becomin Promote nt me nt of	Interest of the Future contracts held at the time of becoming Promoter/appoi nt me		Open Interest of the Option Contracts held at the time of becoming Promoter/app oint me nt of Director/KMP	
1	2	3	Type of security (For eg. – Shares, Warrants , Convertib le Debentur es etc.)	No.	6	Numb er of units (contr acts * lot siz e)	Notio nal value in Rupe e term s	Numb er of units (contr acts * lot siz e)	Notio nal value in Rupe e term s	
T		٦	4	J	U	/		0		

Note: "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of InsiderTrading) Regulations, 2015.

Signature:	
Designation:	
Date:	
Place:	



FORM C

Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7 (2) read with Regulation 6 (2)]

Name of the company: QMS MEDICAL ALLIED SERVICES LIMITED

Details of change in holding of Securities of Promoter, Employee or Director of a listed company and othersuch persons as mentioned in Regulation 6(2).

me, e PAN gc No., y CIN Pe / or DIN (P , m & er addr Kr ess / of Di Pro c m to oter / / im Emp e I did	e gor y of Pers on (Pro mot ers/ KMP / Dire c tors / imm e diat	gor prior to acquisi n/ disposa (Pro mot ers/ KMP / Dire c tors / imm e diat Type		Securi acquired Disposed Type of security (For eg. – Shar es , Warr ants, Conv e	ed/	Shareh olding Pr Po		Date of allotm ent advic e/ acquis ition of share s/ sale of share s specif y F To		Da t e of int i m at io n to co mp an y	Mode of acqui sition (mar ket purch a se/pu blic rights / prefe re ntial offer / off mark et	Trading in derivatives (Specify type of contract, Futures or Options etc) Buy Sell Va Nu Va Numb			Exchan ge on which the trade was execute d	
oye e / Dire c tor with cont act nos.	e rela ti ves / oth ers etc.)	of secur ity (For eg Shar es , Warr ants, Conv e rtibl e Debe nt ure s etc.)	0.	rtible Debe n tures etc.)	6	e tra ns a cti on	st tr a ns a cti on	r o m	10	11	Inte r- se trans fer etc.	l ue	m ber of unit s (co nt ract s * lot size)	ue	er of units (cont racts * lot size)	17

QMS Medical Allied Services Ltd.

🗣 1A-1B / 2A-2B, Navkala Bharati Building, Plot No. 16, Prabhat Colony, Road No. 3, Santacruz (East), Mumbai - 400 055.

☎ +91-022 - 6288 1111 **⊕** www.qmsmas.com



Note: "Secur	ities" shall	have the	meaning	as c	defined	under	regulation	2(1)(i)	of	SEBI
(Prohibition o	f InsiderTr	ading) Re	gulations,	201	5.					
Signature:										

Designation:

Date:

Place:



CODE OF CONDUCT FOR BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL CODE OF CORPORATE DISCLOSURE PRACTICES

Overseeing and co-ordinating disclosure:

The Board of the Company shall designate a senior officer as a Chief Investor Relations Officer who would be responsible to ensure timely, adequate, uniform and universal dissemination of information and disclosure of Unpublished Price Sensitive Information ("**UPSI**") pursuant to this Code as required under the Regulations so as to avoid selective disclosure.

The Chief Investor Relations Officer shall report to the Managing Director/Chief Executive Officer as the case may be and shall also co-ordinate with the Compliance Officer. The Chief Investor Relations Officer shall ensure that information shared with analysts and research personnel is not UPSI. The Chief Investor Relations Officer shall be responsible for overseeing and co-ordinating disclosure of UPSI to analysts, shareholders and media, and educating Employees on disclosure policies and procedures.

The Chief Investor Relations Officer shall also ensure that when interacting with media and external public, guidelines for disclosure of UPSI are complied with.

All disclosure / dissemination of any UPSI (save and except disclosure required to be made under any law or under this Code) on behalf of the Company shall be first marked to the Chief Investor Relations Officer, for approval. Any such information shall be made public or published on behalf of the Company only if the same is approved by the Chief Investor Relations Officer. In case of doubt, the Chief Investor Relations Officer, shall consult and seek approval of the Managing Director/ Chief Executive Officer before dissemination of such information.

Should any dissemination of information on behalf of the Company take place without prior approval referred above, out of accidental omission, selectively, inadvertently or otherwise by any Employee/Director of the Company then such Employee/Director of the Company shall forth within form the Chief Investor Relations Officer, about such disclosure. The Chief Investor Relations Officer will then promptly disseminate the informations as to make such information generally available.

Responding to market rumours:

The Employee/ Director of the Company shall promptly direct any queries on news report so requests for verification of market rumours received from regulatory authorities to the Chief Investor Relations Officer.

The Chief Investor Relations Officer shall on receipt of request s as aforesaid,



consult the Managing Director/Chief Executive Officer as the case may be and send an appropriate and fair response to the same.

The Chief Investor Relations Officer shall be responsible for deciding in consultation with the Managing Director/Chief Executive Officer of the Company as to the necessity of a public announcement for verifying or denying rumours and thereafter making appropriate disclosures.

All requests/queries received shall be documented and as far as practicable, the Chief Investor Relations Officer shall request for such queries/requests in writing. No disclosure in response to the queries/request shall be made by the Chief Investor Relations Officer, unless the Managing Director/Chief Executive Officer approves the same.

<u>Disclosure/dissemination of UPSI with special reference to analysts, institutional investors:</u>

No person, except those authorized by the Chief Investor Relations Officer, shall disclose any information relating to the Company's Securities to analysts and research persons. The Chief Investor Relations Officer, shall be invited to meetings/conferences organized by the Company with analysts/research persons.

All Directors and Employees of the Company should follow the guidelines given hereunder while dealing with analysts and institutional investors.

Sharing of UPSI:

The Employee and Director of the Company shall provide only public information to analysts/research persons. In case any UPSI is proposed to be provided, the person proposing to so provide information shall consult the Chief Investor Relations Officer, in advance. The Chief Investor Relations Officer shall ensure that that the information provided to the analyst/research person/investor as above is made public simultaneously with such disclosure.

The Company shall take extreme care and caution when dealing with analysts" questions that raise issues outside theintended scope of discussion.

The Chief Investor Relations Officer should tackle the unanticipated questions carefully. The unanticipated questions may be noted and a considered response be given later in consultation with the Managing Director/Chief Executive Officer. If the answer to any question requires dissemination of UPSI, the Chief Investor Relations Officer, shall report the same to the Managing Director/Chief Executive Officer and obtain necessary approval for its dissemination to the Stock Exchanges/public announcement through press. The Chief Investor Relations Officer, shall, after dissemination of such UPSI, respond to such unanticipated questions.



The Chief Investor Relations Officer shall handle all the UPSI on a need-to-know basis only. In case of doubt, the Chief Investor Relations Officer, shall consult and seek approval of the Managing Director/Chief Executive Officer before dissemination of such information.

Recording of discussion:

All analyst and other investor relations conferences shall be attended by the Chief Investor Relations Officer who may be accompanied by any other Employee(s) of the Company. In order to avoid misquoting or misrepresentation, the Chief Investor Relations Officer can make transcripts or arrangements for recording the discussions at the meeting.

Simultaneous release of information:

Whenever the Company proposes to organise meetings with investment analysts/research person, the Company shall make a press release or post relevant information on its website after every such meeting. The Company may also consider live webcasting of analyst meets.

The Chief Investor Relations Officer, shall be responsible for drafting of the press release or the text of the information to be posted on the Company's web-site, in consultation with the Managing Director/Chief Executive Officer.

Medium of disclosure/dissemination:

The Company shall disseminate all credible and concrete UPSI on a continuous and immediately manner to Stock Exchanges where its securities are listed in accordance with the requirements of applicable law and thereafter to the press.

As a good corporate practice, the UPSI disclosed to the Stock Exchanges and to the Press may also be supplemented by prompt updates on the Company's website. The Company may also consider other modes of public disclosure of UPSI so as to improve investor access to the same.

The information filed by the Company with the Stock Exchanges under the Stock Exchange Listing Agreement shall also be posted on the Company's website.

The Company will also promptly intimate any amendment to this Code of Corporate Disclosure Practices to the Stock Exchanges, as required under the Regulations.
